FDA Tries to Speed OTC Naloxone Products

The FDA has announced new efforts to expand naloxone access by making it easier for companies to make over-the-counter (OTC) versions of the opioid overdose treatment.

FDA Press Release

← Prev: Sexual Minorities More Likely to Suffer Severe Substance Use Disorders Next: Patterns in Outpatient Benzodiazepine Prescribing in the United States →

You May Also Like…

AMA 2025 Report on Substance Use and Treatment Sees Drop in Overdose Deaths, Calls on Policymakers to Remove Obstacles to Evidence-based Care

AMA 2025 Report on Substance Use and Treatment Sees Drop in Overdose Deaths, Calls on Policymakers to Remove Obstacles to Evidence-based Care

March 31, 2026

The American Medical Association’s 2025 Report on Substance Use and Treatment notes a decline in overdose deaths while...

Scientists Discover Why Mental Disorders So Often Overlap

Scientists Discover Why Mental Disorders So Often Overlap

March 24, 2026

A massive global genetics study is reshaping how we understand mental illness and why diagnoses so often pile up. By...

New Federal Privacy Rules for Substance Use Disorder Records: What Ketamine and Psychedelic Providers Need to Know

New Federal Privacy Rules for Substance Use Disorder Records: What Ketamine and Psychedelic Providers Need to Know

March 17, 2026

The regulatory landscape for substance use disorder (SUD) treatment records is changing—and the impact will extend far...

0 Comments

Submit a Comment Cancel reply